These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33535836)

  • 1. An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy.
    Rau M; Geier A
    Expert Rev Clin Pharmacol; 2021 Mar; 14(3):333-340. PubMed ID: 33535836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and new pharmacotherapy options for non-alcoholic steatohepatitis.
    Sumida Y; Yoneda M; Ogawa Y; Yoneda M; Okanoue T; Nakajima A
    Expert Opin Pharmacother; 2020 Jun; 21(8):953-967. PubMed ID: 32237916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future pharmacological therapies for NAFLD/NASH.
    Sumida Y; Yoneda M
    J Gastroenterol; 2018 Mar; 53(3):362-376. PubMed ID: 29247356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.
    Wang K; Zhang Y; Wang G; Hao H; Wang H
    Med Res Rev; 2024 Mar; 44(2):568-586. PubMed ID: 37899676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obeticholic acid for the treatment of nonalcoholic steatohepatitis.
    Shah RA; Kowdley KV
    Expert Rev Gastroenterol Hepatol; 2020 May; 14(5):311-321. PubMed ID: 32241197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
    Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
    Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
    Venetsanaki V; Karabouta Z; Polyzos SA
    Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-drug approaches to NASH: what's in the development pipeline?
    Johnston MP; Patel J; Byrne CD
    Expert Opin Investig Drugs; 2020 Feb; 29(2):143-150. PubMed ID: 31524533
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-diabetic drugs and NASH: from current options to promising perspectives.
    Smati S; Canivet CM; Boursier J; Cariou B
    Expert Opin Investig Drugs; 2021 Aug; 30(8):813-825. PubMed ID: 34214406
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies.
    Jahn D; Rau M; Wohlfahrt J; Hermanns HM; Geier A
    Dig Dis; 2016; 34(4):356-63. PubMed ID: 27170389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists.
    Shah RA; Alkhouri N; Kowdley KV
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):251-260. PubMed ID: 32686578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Therapies for Nonalcoholic Fatty Liver Disease.
    Hameed B; Terrault N
    Clin Liver Dis; 2016 May; 20(2):365-85. PubMed ID: 27063275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success.
    Drenth JPH; Schattenberg JM
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1365-1375. PubMed ID: 33074035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis.
    Iwaki M; Yoneda M; Wada N; Otani T; Kobayashi T; Nogami A; Saito S; Nakajima A
    Expert Opin Emerg Drugs; 2024 Jun; 29(2):127-137. PubMed ID: 38469871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L; Pruzanski M; Shapiro D
    Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving Role for Pharmacotherapy in NAFLD/NASH.
    Attia SL; Softic S; Mouzaki M
    Clin Transl Sci; 2021 Jan; 14(1):11-19. PubMed ID: 32583961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.